Generic placeholder image

Reviews on Recent Clinical Trials

Editor-in-Chief

ISSN (Print): 1574-8871
ISSN (Online): 1876-1038

Mini-Review Article

Is There an Association between 5a Reductase Inhibitors and Metabolic Syndrome? A Narrative Review of the Literature

Author(s): Afroditi Ziogou, Alexios Giannakodimos, Evangelia Mitakidi, Tzelepis Konstantinos and Ilias Giannakodimos*

Volume 19, Issue 4, 2024

Published on: 11 June, 2024

Page: [229 - 235] Pages: 7

DOI: 10.2174/0115748871303638240529160610

Price: $65

Abstract

Finasteride and dutasteride are 5a Reductase Inhibitors (5a-RIs) and comprise the mainstay of treatment for the management of patients with benign prostatic hyperplasia. 5a-RIs are expressed in a variety of tissues, such as adipose tissues and liver, resulting in a reduction of glucocorticoid levels and affecting androgen regulation and metabolic function. As a result, the administration of these regimens may generate adverse metabolic events, such as liver disease, hyperglycemia, hyperlipidemia, and diabetes mellitus. Although several studies have tried to record these adverse metabolic events both in human subjects and animal models, the exact mechanisms of these actions have not been well described yet in the literature. Further well-designed clinical trials are needed to elucidate the exact role of 5a reductase inhibitors in the progression of the metabolic syndrome. The aim of this study was to systematically review the literature concerning the role of dutasteride or finasteride in the progression of metabolic adverse events and further investigate possible pathophysiologic mechanisms.

Keywords: 5a reductase inhibitors, dutasteride, finasteride, benign prostatic hyperplasia, metabolic syndrome, diabetes mellitus.

Next »

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy